The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Osteoporosis Experts Discuss Bisphosphonate Holidays

Osteoporosis Experts Discuss Bisphosphonate Holidays

November 24, 2020 • By Susan Bernstein

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Dr. Hansen photo

Dr. Hansen

ACR CONVERGENCE 2020—Bisphosphonates are an important treatment for millions of older Americans with osteoporosis because the drugs inhibit osteoclastic bone resorption to reduce the risk of painful, debilitating fractures.1

You Might Also Like
  • Osteoporosis Experts Discuss Bisphosphonates, Chronic Kidney Disease
  • Rheumatology Drug Updates: Hip Fracture Rates After Bisphosphonate Drug Holidays, Plus More on Golimumab, Ustekinumab
  • Bisphosphonate Drug Holiday & Hip Fracture Risk
Also By This Author
  • Proposed 2020 E/M Codes Include Reimbursement Changes

More than 20 years ago, data emerged that bisphosphonates have a long terminal half-life.2 So after years of therapy, could some patients take a drug holiday? At the ACR Convergence 2020 session Bone for the Holidays: Antiresorptives, Atypical Fractures and Other Adverse Events, osteoporosis experts shared updated treatment recommendations on bisphosphonate holidays and discussed serious, atypical fractures that affect a small number of patients who take bisphosphonates and even those who have discontinued therapy.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Bisphosphonate holiday benefits include a reduced risk of such side effects as osteonecrosis of the jaw, subtrochanteric fractures and gastric irritation, although one concern is patients could have another fracture, said rheumatologist Karen E. Hansen, MD, MS, professor of medicine at the University of Wisconsin School of Medicine and Public Health, Madison.

“A person taking a drug holiday might have a decline in bone density or may be lost to follow-up and then have a fracture. They may reduce their adherence to a bone-healthy lifestyle—including exercise, adequate calcium and vitamin D intake, and avoidance of bone toxins like alcohol and tobacco,” Dr. Hansen said.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Fracture Risk Differences

Two major trials explored holiday benefits and risks. In an extension trial of 2,629 post-menopausal women who had already received three annual doses of intravenous zoledronic acid, participants received either three more years of zoledronate or placebo.3 Women who continued zoledronic acid had fewer vertebral fractures, but other fractures were not reduced, and the absolute difference in fracture risk between the two groups was 3%, small but significant.

In another trial, 3,236 post-menopausal women who had previously taken three or more years of alendronate and who also had either stable or increased hip T-score above -3.5 were recruited for an extension trial. After some exclusions, 1,099 women were randomized to receive either alendronate or placebo for five or 10 more years. The primary outcome for this trial was total hip bone mineral density, which did drop slightly in the placebo group. But bone density was maintained in the trochanter and femoral neck bones, and it also rose in the lumbar spines of patients in the placebo group.4

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“What was fascinating was that there was no difference in radiographic vertebral fractures or non-spine fractures whether the women took alendronate for five or 10 years,” said Dr. Hansen. “There was a small difference in painful compression fractures in this trial, with a benefit to continue alendronate.”

Pages: 1 2 3 4 5 6 | Single Page

Filed Under: ACR Convergence, Conditions, Meeting Reports Tagged With: ACR Convergence 2020, Bisphosphonate, bone mineral density (BMD), drug holiday, Fractures, Osteoporosis

You Might Also Like:
  • Osteoporosis Experts Discuss Bisphosphonates, Chronic Kidney Disease
  • Rheumatology Drug Updates: Hip Fracture Rates After Bisphosphonate Drug Holidays, Plus More on Golimumab, Ustekinumab
  • Bisphosphonate Drug Holiday & Hip Fracture Risk
  • New Bisphosphonate Therapy Recommendations for Postmenopausal Osteoporosis

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.